1. FDA Approved Labeling. Veklury (remdesivir). Highlights of prescribing information. Revised: 06/2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787Orig1s015lbl.pdf.
2. FDA Approved Labeling. Olumiant (baricitinib). Highlights of prescribing information. Revised: 05/2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf. 2022.
3. U.S. Food & Drug Administration. Coronavirus (COVID-19) | Drugs. https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs.
4. U.S. Food & Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of Veklury® (remdesivir). August 2020. https://www.fda.gov/media/143189/download.
5. Gilead. Veklury: Annex I: summary of product characteristics. Revised June 2023. https://veklury.eu/ie/media_uploads/2023/07/UK-Ireland-Malta-Veklury-SmPC-PDF-1.pdf.